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The usage of ivermectin (ivm) to treat COVID-19 is 
controversial. According to a study, ivermectin helped treat 
COVID-19, but clinical trials showed that ivermectin with 
the tetracycline-class antibiotic doxycycline overcame the 
effects of ivermectin to a certain degree2. The goal of this 
project is to understand why this occurs. Cell cultures were 
used as a model. Rather than overcoming the effects of 
ivermectin, tetracycline seems to prevent ivermectin from 
mitochondrial inhibition. This effect seems to occur when 
tetracycline is administered first, with ivermectin 
administered after one hour or more; the effect is 
prevented when ivermectin is administered, left for two 
hours, and then tetracycline is added and left for one hour.
Hydroxycholoroquine (HCQ) has been shown to be a 
possible therapeutic in the treatment of COVID-19. It is an 
antimalarial drug, and part of its mechanism of action, 
according to studies, suggests that it sequesters protons in 
the intermembrane space of the mitochondria. Some data 
suggests that COVID-19 hijacks the mitochondria and 
sequesters protons, destroying the proton gradient required 
for ATP production and causing eventual cell death1. In 
this way, (HCQ) could show therapeutic effects by 
sequestering the protons in a gradual fashion. HCQ is 
therefore used as a control.
The study showing that ivm+doxycycline shows lower 
viral clearance than ivm alone presents the following 
graph2:
Ivm is an antiparasitic. Doxycycline is an antibiotic 
often used to prevent secondary infection in diseases that 
compromise lung function.
• Using tetracycline (tet) as the antibiotic, varying concentrations.
• Varying concentrations of ivermectin (ivm).
• Hydroxychloroquine (HCQ) used as a control (various concentrations). 
• Availability
• Appears to target mitochondria in a different way than ivermectin
• See if antibiotic overcomes both mitochondrial inhibitors (HCQ and ivm) 
that function differently. 
• Use of Cell Titer Glo assay:
• 15k cells in 100 microliters media per well in a 96-well polystyrene 
assay plate. Add drugs and incubate for two hours.
• Add CTG reagent, causing cell lysis and ATP release, used to generate 
luminescence. Measure cell viability based on ATP production.
Figure 1 shows that tet affects ivm but not HCQ. Figure 2 
shows inhibition decreases (signal increases) with 
decreasing concentration of ivm, and tet affects ivm to a 
certain extent (i.e. maximum signal). Order of addition 
with ivm 1 hour, then tet 2 hours (not shown) shows time 
dependence of ivm, but no statistical difference between 
ivm and ivm+tet conditions. Figure 3 shows less 
inhibition from ivm with addition of tet, proving that 
instead of overcoming inhibition, tet is probably 
preventing ivm from mitochondrial inhibition. However, 
tet could be reestablishing a switch to glycolysis instead 
to compensate for inhibited mitochondria. 
• See whether tet is re-establishing switch to glycolysis 
or preventing ivm mitochondrial inhibition.
• Finding a class of antibiotics that has the same 
preventative measures as doxycycline without affecting 
ivermectin.
• Maximize efficiency of treatment with protection of 
antibiotic.
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Ivermectin acts on the mitochondria to inhibit ATP 
synthesis, and adding tetracycline overcomes 
mitochondrial inhibition.
Figure 1. Various concentrations of tet with constant HCQ and ivm
concentrations on h293 cells (kidney epithelial cancer cells)
Figure 2. Various concentrations of ivm while adding 50 mM tet (most 
effective) on a549 cells (lung epithelial cancer cells)
Figure 3. Order of addition, tet for 1 hour then add ivm, wait for 2 hours
